Reply to Viel

By sjmartinez • July 12, 2022

Recknor C, Hansen SG, Gaylis NB, Tiwary M, Sacha JB, Yang OO. Reply to Viel. Clin Infect Dis. 2022 Jul 12:ciac390. doi: 10.1093/cid/ciac390. Epub ahead of print. PMID: 35819204.

Tags: Infectious Diseases, Publications

Assessment of disability and disease burden in neuromyelitis optica spectrum disorders in the CIRCLES Cohort

Gholizadeh S, Exuzides A, Sinnott J, Palmer C, Waltz M, Rose JW, Jolley AM, Behne JM, Behne MK, Blaschke TF, Smith TJ, Lewis KE, Cook[...]

Preparing better: Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) therapeutics trials lessons learned: A call to the future

Adam SJ, Buchman TG, Currier JS, Draghia-Akli R, Fessel JP, Higgs ES, Hughes EA, LaVange L, Menetski JP, Read SW, Rosenberg Y, Tressler R; ACTIV[...]

ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic

Keshtkar-Jahromi M, Anstrom KJ, Barkauskas C, Brown SM, Daar ES, Fischer W, Gibbs KW, Higgs ES, Hughes MD, Jagannathan P, LaVange L, Lindsell CJ, Nayak[...]